Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
ARPC1B binds WASP to control actin polymerization and curtail tonic signaling in B cells
Gabriella Leung, … , Aleixo M. Muise, Spencer A. Freeman
Gabriella Leung, … , Aleixo M. Muise, Spencer A. Freeman
Published October 21, 2021
Citation Information: JCI Insight. 2021;6(23):e149376. https://doi.org/10.1172/jci.insight.149376.
View: Text | PDF
Research Article Cell biology Immunology

ARPC1B binds WASP to control actin polymerization and curtail tonic signaling in B cells

  • Text
  • PDF
Abstract

Immune cells exhibit low-level, constitutive signaling at rest (tonic signaling). Such tonic signals are required for fundamental processes, including the survival of B lymphocytes, but when they are elevated by genetic or environmental causes, they can lead to autoimmunity. Events that control ongoing signal transduction are, therefore, tightly regulated by submembrane cytoskeletal polymers like F-actin. The actin-binding proteins that underpin the process, however, are poorly described. By investigating patients with ARPC1B deficiency, we report that ARPC1B-containing ARP2/3 complexes are stimulated by Wiskott Aldrich Syndrome protein (WASP) to nucleate the branched actin networks that control tonic signaling from the B cell receptor (BCR). Despite an upregulation of ARPC1A, ARPC1B-deficient cells were not capable of WASP-mediated nucleation by ARP2/3, and this caused the loss of WASP-dependent structures, including podosomes in macrophages and lamellipodia in B cells. In the B cell compartment, ARPC1B deficiency also led to weakening of the cortical F-actin cytoskeleton that normally curtails the diffusion of BCRs and ultimately resulted in increased tonic lipid signaling, oscillatory calcium release from the endoplasmic reticulum (ER), and phosphorylated Akt. These events contributed to skewing the threshold for B cell activation in response to microbial-associated molecular patterns (MAMPs). Thus, ARPC1B is critical for ARP2/3 complexes to control steady-state signaling of immune cells.

Authors

Gabriella Leung, Yuhuan Zhou, Philip Ostrowski, Sivakami Mylvaganam, Parastoo Boroumand, Daniel J. Mulder, Conghui Guo, Aleixo M. Muise, Spencer A. Freeman

×

Figure 4

The loss of cortical ARPC1B-containing ARP2/3 complexes increases spontaneous, oscillatory calcium signaling, phospho-Akt, and CD86 expression.

Options: View larger image (or click on image) Download as PowerPoint
The loss of cortical ARPC1B-containing ARP2/3 complexes increases sponta...
(A and B) Control (CK-689) or CK-666–treated Ramos B cells loaded with the Fluo-8 calcium sensor were imaged every 10 seconds for 5 minutes; they were then treated with the PLC inhibitor U73122 and imaged for another 5 minutes (middle panel). Ensemble traces are shown in A. (B) The variance (deviation from the mean) was determined as a measure of [Ca2+]cytosol flux. Greater than 50 cells were used; n = 3. (C and D) WT and ARPC1B-KO Ramos cells imaged and quantified as in A. Cells were treated with the SYK inhibitor BAY 61-3606 for 10 minutes and imaged for another 5 minutes. (D) The variance was determined as a measure of [Ca2+]cytosol flux. Greater than 50 cells were used; n = 3. (E) Ramos cells blotted for AKT and ERK phosphorylation at indicated times after addition of CK-666. Results were assessed using a 1-way ANOVA and Dunnett’s test comparing all groups to the DMSO control; n = 6. (F) Unstimulated WT and ARPC1B-KO Ramos cells blotted for ERK phosphorylation. (G) Primary B cells given Control (CK-689) or CK-666 overnight together with 100 ng/mL LPS. Representative surface CD86 by FACS is shown; n = 3. *P < 0.05; ****P < 0.0001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts